XML 246 R200.htm IDEA: XBRL DOCUMENT v3.24.0.1
Other operating expenses - Other Income and Expense (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses € (3,516) € (2,531) € (1,805)
Other operating income 1,292 1,969 859
Other operating income/(expenses), net related to Regeneron (2,979) (1,231) (1,373)
Antibodies Collaboration agreement | Regeneron Pharmaceuticals, INC      
Disclosure Of Other Operating Income Expenses [Line Items]      
Commitments received for development costs 2,100 2,700  
Regeneron      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses (3,206) (2,378) (1,568)
Other operating income (expense) | Regeneron      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income 227 1,147 195
Monoclonal Antibody Alliance      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses (3,196) (2,367) (1,429)
Monoclonal Antibody Alliance | Share of profit or loss from commercialization of monoclonal antibodies      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses (3,321) (2,325) (1,253)
Monoclonal Antibody Alliance | Share of profit or loss from commercialization of Zaltrap      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income 668 434 127
Monoclonal Antibody Alliance | Commercialization related expenses      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating expenses (543) (476) (303)
Immuno-Oncology Alliance      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income 0 16 68
Others      
Disclosure Of Other Operating Income Expenses [Line Items]      
Other operating income and expenses € 217 € 1,120 € (12)